Insights

Innovative Diagnostic Tool NIOX VERO® is a cutting-edge, non-invasive device for asthma diagnosis and monitoring, offering healthcare providers a reliable solution for FeNO testing across various clinical settings. This positions the company as a leader in respiratory diagnostics with strong potential for expanding adoption through targeted outreach and training programs.

Growing Strategic Partnerships Recent collaborations with Vitalograph Inc and the AHSN Network highlight NIOX’s efforts to enhance distribution and accessibility of its products. These partnerships open avenues for scaling sales in both clinical and primary care markets, especially in regions emphasizing integrated healthcare solutions.

Market Leadership and Reputation As the global leader in FeNO testing with a strong reputation for innovation, NIOX demonstrates trust and credibility among healthcare professionals, creating opportunities to expand its product portfolio and deepen market penetration in respiratory diagnostics.

Focus on Healthcare Provider Support NIOX’s commitment to offering training and support enhances user engagement and satisfaction, making it easier for sales teams to promote the device and foster long-term relationships with clinical clients seeking reliable asthma management solutions.

Potential for Market Expansion With a revenue range of 1 to 10 million and a specialized product lineup, NIOX is well-positioned to enter new geographic markets and respiratory health segments, especially leveraging its expert reputation and recent collaborative efforts to drive further sales growth.

Similar companies to NIOX®

NIOX® Tech Stack

NIOX® uses 8 technology products and services including BootstrapCDN, Open Graph, RSS, and more. Explore NIOX®'s tech stack below.

  • BootstrapCDN
    Content Delivery Network
  • Open Graph
    Content Management System
  • RSS
    Content Management System
  • GSAP
    Javascript Frameworks
  • Floating UI
    Javascript Libraries
  • UNIX
    Operating Systems
  • FedEx
    Transportation And Fleet Management
  • Google Analytics
    Web Analytics

NIOX®'s Email Address Formats

NIOX® uses at least 2 format(s):
NIOX® Email FormatsExamplePercentage
First.Last@circassia.comJohn.Doe@circassia.com
85%
FirstLast@circassia.comJohnDoe@circassia.com
4%
First.Middle@circassia.comJohn.Michael@circassia.com
1%
First-Last@circassia.comJohn-Doe@circassia.com
2%
FiLast@circassia.comJoDoe@circassia.com
1%
First_Last@circassia.comJohn_Doe@circassia.com
1%
Last.First@circassia.comDoe.John@circassia.com
1%
LastFir@circassia.comDoeJoh@circassia.com
1%
FirstLa@circassia.comJohnDo@circassia.com
1%
F-Last@circassia.comJ-Doe@circassia.com
1%
Last.F@circassia.comDoe.J@circassia.com
1%
First@circassia.comJohn@circassia.com
1%
First.Last@niox.comJohn.Doe@niox.com
71%
FirLast@niox.comJohDoe@niox.com
17%
FiLast@niox.comJoDoe@niox.com
6%
FLast@niox.comJDoe@niox.com
6%

Frequently Asked Questions

Where is NIOX®'s headquarters located?

Minus sign iconPlus sign icon
NIOX®'s main headquarters is located at Oxford, England ox4 4gb United Kingdom. The company has employees across 3 continents, including EuropeNorth AmericaAsia.

What is NIOX®'s phone number?

Minus sign iconPlus sign icon
You can contact NIOX®'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is NIOX®'s stock symbol?

Minus sign iconPlus sign icon
NIOX® is a publicly traded company; the company's stock symbol is CIR.L.

What is NIOX®'s official website and social media links?

Minus sign iconPlus sign icon
NIOX®'s official website is niox.com and has social profiles on LinkedIn.

What is NIOX®'s SIC code NAICS code?

Minus sign iconPlus sign icon
NIOX®'s SIC code is 2835 - In Vitro and In Vivo Diagnostic Substances NAICS code is 325412 - Pharmaceutical Preparation Manufacturing.

How many employees does NIOX® have currently?

Minus sign iconPlus sign icon
As of March 2026, NIOX® has approximately 88 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Financial Officer: S. D.Regional Vice President, Emea: W. S.Senior Vice President, Americas & Global Research Business: T. S.. Explore NIOX®'s employee directory with LeadIQ.

What industry does NIOX® belong to?

Minus sign iconPlus sign icon
NIOX® operates in the Medical Equipment Manufacturing industry.

What technology does NIOX® use?

Minus sign iconPlus sign icon
NIOX®'s tech stack includes BootstrapCDNOpen GraphRSSGSAPFloating UIUNIXFedExGoogle Analytics.

What is NIOX®'s email format?

Minus sign iconPlus sign icon
NIOX®'s email format typically follows the pattern of First.Last@circassia.com. Find more NIOX® email formats with LeadIQ.

When was NIOX® founded?

Minus sign iconPlus sign icon
NIOX® was founded in 2006.

NIOX®

Medical Equipment ManufacturingEngland, United Kingdom51-200 Employees

NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO®, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma.

NIOX VERO® provides accurate and reliable results, allowing healthcare
professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, and can be used in a variety of settings, including clinics, hospitals, and primary care settings.

The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX® is also committed to offering additional training and support for healthcare professionals.

Overall, NIOX Group plc is the global leader in FeNO testing, with a strong
reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO®, healthcare professionals have a reliable and non-invasive tool to help them better diagnose and manage asthma.

References:
1. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218.
2. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1
3. Busse WW et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173.
4. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633.
5. NIOX®. Data on File; MKT-DOF-007.

Section iconCompany Overview

Headquarters
Oxford, England ox4 4gb United Kingdom
Phone number
Website
niox.com
SIC Code
2835 - In Vitro and In Vivo Diagnostic Substances
Stock Symbol
CIR.L
NAICS Code
325412 - Pharmaceutical Preparation Manufacturing
Founded
2006
Employees
51-200

Section iconFunding & Financials

  • $1M$10M

    NIOX®'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    NIOX®'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.